What 23 Analyst Ratings Have To Say About Eli Lilly and Co
In the preceding three months, 23 analysts have released ratings for Eli Lilly and Co (NYSE:LLY), presenting a wide array of perspectives from bullish to bearish. The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
Eli Lilly, Q1
Eli Lilly boosts production for obesity and diabetes drugs, reports mixed Q1 results. Expectations for supply growth in 2024 ...
1don MSN
Zepbound reported $517.4 million in sales for the quarter, even as most doses of the drug slipped into shortages in the U.S.
Eli Lilly stock jumped 5% during Tuesday morning trading to about $773 a share after the pharma giant reported ...
Eli Lilly shares popped early Tuesday after the drugmaker reported first-quarter profit that topped estimates amid strong ...
Drugmaker Eli Lilly's stock jumped Tuesday as weight loss drugs Mounjaro and Zepbound continue to boost revenue and profits.
Pacers Sports & Entertainment and Eli Lilly and Company have reached an agreement to make the Indiana-based medicine company ...
Strong sales of Eli Lilly’s diabetes and obesity therapies have prompted an upgrade for the full year - Head of Equity ...
On April 30th Eli Lilly, maker of a hit weight-loss treatment, delivered another dose of strong quarterly results. On May 2nd ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback